Abstract 2104P
Background
Common side effects of taxanes are nail toxicity (tox) and CIPN. Different methods of cryotherapy to prevent these side effects have been tested. We investigated machine-controlled cooling of hand and feet to reduce nail tox and CIPN.
Methods
Patients (pts) receiving Docetaxel (Doce) (planned dose 300mg/m2) or Paclitaxel (Pacli) (planned dose 720mg/m) in the adjuvant or palliative setting were included. The dominant hand and foot were cooled to approximately 10°C using the Hilotherapy-machine. The contralateral hand and foot were used as intrapatient comparison. Primary endpoint was the occurrence of any nail tox (Doce cohort) or CIPN (Pacli cohort) at any time during and up to 56 days after the end of treatment. We assumed an absolute improvement of 40% in nail tox and 20% in CIPN. With 90% power using a two-sided McNemar test with a significance level of 5%, a total of 30 pts were needed in each group. The intended to treat population (ITT) and the per protocol population (PPP) were analysed. Toxicity was assessed using the CTCAE v5.0 grading system and the PNQ questionnaire.
Results
69 pts, 21 (9 in the PPP) treated with Doce and 48 (34 in the PPP) treated with Pacli, were included from 08/2020 - 08/2022. In the Doce cohort, nail tox was not significantly improved by cooling in the ITT (81.0%, vs 85.7%; odds ratio (OR) 0.71, 95% CI: 0.14 – 3.64, p = 0.564) and PPP (100% vs 100%; OR: 1.00, 95% CI: 0.00 – NA, p = NA) but significant benefit across visits over time was found for the ITT (OR: 0.42, 95% CI: 0.18 – 0.98, p=0.045) but not the PPP (OR: 0.75, 95% CI: 0.30 – 1.86, p=0.529). In the Pacli cohort, CIPN was numerically better in the ITT (60.9% vs. 71.7%, OR: 0.61, 95% CI: 0.26 – 1.47, p=0.059) and significantly better in the PPP (67.6% vs. 82.4%, OR: 0.45, 95% CI: 0.14 – 1.40, p-value = 0.025). Differences across visits were significantly in favour of cooling (ITT: OR: 0.28, 95% CI: 0.13 - 0.57, p=0.001; PPP: OR: 0.25, 95% CI: 0.12 - 0.55, p=0.001). Cooling was well tolerated, only 6 pts (9%) discontinued due to side effects.
Conclusions
Cooling of hand and feet has a clinically meaningful impact on occurrence of CIPN and nail toxicity. Effects are more significant over time and are taxane dose dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantonsspital Graubünden, Chur, Switzerland.
Funding
Has not received any funding.
Disclosure
R. Cathomas: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS, Bayer, MSD, Roche, Sanofi, Astellas, Ipsen, Merck, Pfizer, Debiopharm; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Janssen, Merck; Financial Interests, Institutional, Invited Speaker: Astellas; Non-Financial Interests, Member of Board of Directors: SAKK Swiss Working Group for Clinical Cancer Research. All other authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06